2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP) ± BEV for ovarian cancer (OC). (September 2015) - Embleton, A.C.; Perren, T.J.; Cook, A.; Kent, E.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Beale, P.; Cervantes, A.; Farrelly, L.; Kaplan, R.; et al.